Mostly Markets
Subscribe
Stocks/Health Care/Biotechnology

IncyteINCY

Biotechnology · Wilmington, Delaware · In the S&P 500
High qualityPricier than peers
$120.39+3.07%After hours: $120.41 (+0.02%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 33.5% over 1 year
Incyte over 1 yearDaily close, $, to 30 Oct 2026
$100Nov2026MarMayJulSep$120.39$100NovMarJul$120.39
Source: Nasdaq daily closes
Market value$24.40B
Price to earnings64.0x
Forward P/E61.0x
Dividend yield–
Year to date+21.9%
One year+33.5%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$90.30$129.93

Quality and valuation

How Incyte compares with other health care stocks. A description, not a recommendation.

Incyte and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: pricier than most

A stronger business than most health care companies, priced above most of them.

Incyte trades at 61.0 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +24.9% vs +7.8%
  • Keeps more of each sale (gross margin): 92.7% vs 65.3%
  • Less profitable (operating margin): 10.4% vs 13.3%
INCY trades at 61.0x forward earnings, above the sector medianForward p/e, Biotechnology peers
REGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1xREGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 64.0x earnings, INCY is cheaper than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
0x200x400x600xAverage 137.2x2025202664.0x0x250x500xAverage 137.2x2025202664.0x
Source: Nasdaq prices; SEC filings

Financials

From Incyte's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 14.0% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0.0bn$0.5bn$1.0bn$1.5bnQ4 ’24Q2 ’25Q4 ’25$1.6bnQ3 ’26$0bn$1bnQ4 ’24Q2 ’25Q4 ’25$1.6bnQ3 ’26
Source: SEC filings
Growth slowed to +14.0% last quarterRevenue growth, year on year, %
0%10%20%30%Q4 ’24Q2 ’25Q4 ’2514.0%Q3 ’260%20%Q4 ’24Q2 ’25Q4 ’2514.0%Q3 ’26
Source: SEC filings
Operating margin was -45.5% last quarterOperating income as a share of revenue, %
−25%0%25%Q4 ’24Q2 ’25Q4 ’25−45.5%Q3 ’260%Q4 ’24Q2 ’25Q4 ’25−45.5%Q3 ’26
Source: SEC filings
Diluted EPS was $-3.86 last quarterQuarterly diluted earnings per share, $
$-2$0$2Q4 ’24Q2 ’25Q4 ’25−$3.86Q3 ’26$-2$0$2Q4 ’24Q2 ’25Q4 ’25−$3.86Q3 ’26
Source: SEC filings
Last 12 monthsINCYSector median
Revenue growth+24.9%+7.8%
Gross margin92.7%65.3%
Operating margin10.4%13.3%
Price to earnings64.0x30.2x

Stories on Incyte

We haven't written about Incyte yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
ABBVAbbVie$294.89+1.41%+29.1%$521B
AMGNAmgen$466.01+1.15%+42.4%$252B
GILDGilead Sciences$170.68+3.06%+39.1%$212B
VRTXVertex Pharmaceuticals$558.88+3.50%+23.3%$142B
REGNRegeneron Pharmaceuticals$927.89+13.33%+20.2%$95.53B
MRNAModerna$221.72−0.47%+651.8%$88.52B
BIIBBiogen$253.62+1.59%+44.1%$37.49B